D
Denis Lacombe
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 180
Citations - 54270
Denis Lacombe is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Clinical trial & Cancer. The author has an hindex of 47, co-authored 171 publications receiving 45726 citations.
Papers
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent,Alba A. Brandes,Martin J.B. Taphoorn,Johan M. Kros,Mathilde C.M. Kouwenhoven,Jean-Yves Delattre,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,László Sipos,Roelien H. Enting,Pim J. French,Winand N.M. Dinjens,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia,Khê Hoang-Xuan +18 more
TL;DR: The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors, and 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/ 19q-deleted tumors.
Journal ArticleDOI
Imaging biomarker roadmap for cancer studies.
James P B O'Connor,Eric O. Aboagye,Judith E. Adams,Hugo J.W.L. Aerts,Hugo J.W.L. Aerts,Sally F. Barrington,Ambros J. Beer,Ronald Boellaard,Sarah E. Bohndiek,J. Michael Brady,Gina Brown,David L. Buckley,Thomas L. Chenevert,Laurence P. Clarke,Sandra Collette,Gary Cook,Nandita M. deSouza,John Dickson,Caroline Dive,Jeffrey L. Evelhoch,Corinne Faivre-Finn,Ferdia A. Gallagher,Fiona J. Gilbert,Robert J. Gillies,Vicky Goh,John R. Griffiths,Ashley M. Groves,Steve Halligan,Adrian L. Harris,David J. Hawkes,Otto S. Hoekstra,Erich P. Huang,Brian Hutton,Edward F. Jackson,Gordon C Jayson,Andrew J. I. Jones,Dow-Mu Koh,Denis Lacombe,Philippe Lambin,Nathalie Lassau,Martin O. Leach,Ting-Yim Lee,Edward Leen,Jason S. Lewis,Yan Liu,Mark F. Lythgoe,Prakash Manoharan,Ross J. Maxwell,Kenneth A. Miles,Bruno Morgan,Steve Morris,Tony Ng,Anwar R. Padhani,Geoff J M Parker,Mike Partridge,Arvind P. Pathak,Arvind P. Pathak,Andrew C. Peet,Shonit Punwani,Andrew R. Reynolds,Simon P. Robinson,Lalitha K. Shankar,Ricky A. Sharma,Dmitry Soloviev,Sigrid Stroobants,Daniel C. Sullivan,Stuart A. Taylor,Paul S. Tofts,Gillian M. Tozer,Marcel van Herk,Simon Walker-Samuel,James Wason,Kaye J. Williams,Paul Workman,Thomas E. Yankeelov,Kevin M. Brindle,Lisa M. McShane,Alan Jackson,John C. Waterton +78 more
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.